Articles from Latent Labs

Today, Latent Labs launches Latent-Y, an AI agent that autonomously designs therapeutic antibodies from a text prompt, compressing weeks of expert work into hours. Powered by Latent-X2, Latent Labs' frontier model for drug-like antibody and peptide design, Latent-Y brings structural drug design to any researcher — no specialist infrastructure required. Latent Labs is opening access to selected partners.

Today, Latent Labs announces Latent-X2, a frontier AI model that can design drug-like biologics without iteration. Drug hunters can use Latent Lab's AI platform, built on Latent-X2, to access difficult targets and accelerate development timelines by reducing wet lab work. The generated designs display drug-like properties including low ex vivo immunogenicity, significantly shortening the path from hit to clinical candidate. Alongside the release, Latent Labs welcomes Stefan Oschmann, former CEO of Merck KGaA, to its strategic advisory board. Latent Labs is opening access to the model for selected partners.

Today, Latent Labs is launching Latent-X, a frontier AI model for push button protein design, outperforming competing models under identical laboratory conditions. The model is available for early access on Latent's no-code AI protein design platform, where users can upload protein targets and generate cyclic peptides and mini-binders directly in the browser. Through the platform, users can generate, explore, and score binder designs, selecting top-ranked structures for further lab testing. The platform includes a free tier for both commercial and non-commercial users. Sign up is available at platform.latentlabs.com.

Latent Labs, the company building AI foundation models to make biology programmable, today emerged from stealth with $50M in total funding to accelerate their progress and partnerships.